Wuthrick EJ, Zhang Q, Machtay M et al.. Institutional clinical trial accrual volume and survival of patients with head and neck cancer. J Clin Oncol 2015;33:156–164.
Eskander A, Irish J, Groome PA et al.. Volume-outcome relationships for head and neck cancer surgery in a universal health care system. Laryngoscope 2014;124:2081–2088.
de Martel C, Ferlay J, Franceschi S et al.. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012;13:607–615.
Gillison ML, Koch WM, Capone RB et al.. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709–720.
Applebaum KM, Furniss CS, Zeka A et al.. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J Natl Cancer Inst 2007;99:1801–1810.
D'Souza G, Kreimer AR, Viscidi R et al.. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944–1956.
Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer 2007;110:1429–1435.
Adelstein DJ, Ridge JA, Gillison ML et al.. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 2009;31:1393–1422.
Agalliu I, Gapstur S, Chen Z et al.. Associations of oral alpha-, beta-, and gamma-human papillomavirus types with risk of incident head and neck cancer [published online ahead of print January 21, 2016]. JAMA Oncol, doi: 10.1001/jamaoncol.2015.5504.
Snow AN, Laudadio J. Human papillomavirus detection in head and neck squamous cell carcinomas. Adv Anat Pathol 2010;17:394–403.
Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612–619.
D'Souza G, Zhang HH, D'Souza WD et al.. Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncol 2010;46:100–104.
Chaturvedi AK, Engels EA, Pfeiffer RM et al.. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29:4294–4301.
Gillison ML, Broutian T, Pickard RK et al.. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307:693–703.
Nasman A, Attner P, Hammarstedt L et al.. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125:362–366.
Mehanna H, Beech T, Nicholson T et al.. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. Head Neck 2013;35:747–755.
Gillison ML, Alemany L, Snijders PJ et al.. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012;30(Suppl 5):F34–54.
Ndiaye C, Mena M, Alemany L et al.. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014;15:1319–1331.
Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861–1868.
- Search Google Scholar
- Export Citation
. Ault KA Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861– 1868.
Herrero R, Quint W, Hildesheim A et al.. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013;8:e68329.
Jordan RC, Lingen MW, Perez-Ordonez B et al.. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 2012;36:945–954.
Weinberger PM, Yu Z, Haffty BG et al.. Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24:736–747.
Cantley RL, Gabrielli E, Montebelli F et al.. Ancillary studies in determining human papillomavirus status of squamous cell carcinoma of the oropharynx: a review. Patholog Res Int 2011;2011:138469.
Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010;116:2166–2173.
Thavaraj S, Stokes A, Guerra E et al.. Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol 2011;64:308–312.
Begum S, Gillison ML, Nicol TL, Westra WH. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:1186–1191.
Ang KK, Harris J, Wheeler R et al.. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35.
Fakhry C, Westra WH, Li S et al.. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261–269.
Rischin D, Young RJ, Fisher R et al.. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010;28:4142–4148.
Fakhry C, Zhang Q, Nguyen-Tan PF et al.. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol 2014;32:3365–3373.
Posner MR, Lorch JH, Goloubeva O et al.. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011;22:1071–1077.
Chung CH, Zhang Q, Kong CS et al.. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 2014;32:3930–3938.
Lassen P, Eriksen JG, Hamilton-Dutoit S et al.. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992–1998.
Wang MB, Liu IY, Gornbein JA, Nguyen CT. HPV-positive oropharyngeal carcinoma: a systematic review of treatment and prognosis. Otolaryngol Head Neck Surg 2015;153:758–769.
RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol 2007;5:79–81.
- Search Google Scholar
- Export Citation
RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for stage III and IV head and neck carcinomas. Clin Adv Hematol Oncol 2007; 5: 79– 81.
Gibson MK, Li Y, Murphy B et al.. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562–3567.
Argiris A, Buchanan A, Brockstein B et al.. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer 2009;115:4504–4513.
Argiris A, Li S, Ghebremichael M et al.. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol 2014;25:1410–1416.
Psyrri A, Rampias T, Vermorken JB. The current and future impact of human papillomavirus on treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2014;25:2101–2115.
Kaczmar JM, Tan KS, Heitjan DF et al.. HPV-related oropharyngeal cancer: risk factors for treatment failure in patients managed with primary transoral robotic surgery. Head Neck 2016;38:59–65.
Dahlstrom KR, Garden AS, William WN Jr et al.. Proposed staging system for patients with HPV-related oropharyngeal cancer based on nasopharyngeal cancer N categories. J Clin Oncol 2016;34:1848–1854.
O'Sullivan B, Huang SH, Siu LL et al.. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013;31:543–550.
Quon H, Forastiere AA. Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: should we, how should we, and for whom? J Clin Oncol 2013;31:520–522.
Masterson L, Moualed D, Masood A et al.. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cochrane Database Syst Rev 2014;2:CD010271.
Kofler B, Laban S, Busch CJ et al.. New treatment strategies for HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol 2014;271:1861–1867.
Marur S, Li S, Cmelak AJ et al.. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN Cancer Research Group [published online ahead of print December 28, 2016]. J Clin Oncol, JCO2016683300.
- Search Google Scholar
- Export Citation
. Marur S Li S Cmelak AJ E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx-ECOG-ACRIN Cancer Research Group [published online ahead of print December 28, 2016]. J Clin Oncol, JCO2016683300.
Gillison ML, Zhang Q, Jordan R et al.. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012;30:2102–2111.
Sinha P, Lewis JS Jr, Piccirillo JF et al.. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer 2012;118:3519–3530.
Spector ME, Gallagher KK, Light E et al.. Matted nodes: poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status. Head Neck 2012;34:1727–1733.
Vainshtein JM, Spector ME, Ibrahim M et al.. Matted nodes: High distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer. Head Neck 2016;38(Suppl 1):E805–814.
Bernier J, Domenge C, Ozsahin M et al.. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945–1952.
Cooper JS, Pajak TF, Forastiere AA et al.. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937–1944.
Bernier J, Cooper JS, Pajak TF et al.. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005;27:843–850.
Sinha P, Piccirillo JF, Kallogjeri D et al.. The role of postoperative chemoradiation for oropharynx carcinoma: a critical appraisal of the published literature and National Comprehensive Cancer Network guidelines. Cancer 2015;121:1747–1754.
Cooper JS, Fortpied C, Gregoire V et al.. The role of postoperative chemoradiation for oropharynx carcinoma: a critical appraisal revisited. Cancer 2017;123:12–16.
Iyer NG, Dogan S, Palmer F et al.. Detailed analysis of clinicopathologic factors demonstrate distinct difference in outcome and prognostic factors between surgically treated HPV-positive and negative oropharyngeal cancer. Ann Surg Oncol 2015;22:4411–4421.
Maxwell JH, Ferris RL, Gooding W et al.. Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer 2013;119:3302–3308.
Sinha P, Kallogjeri D, Gay H et al.. High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer. Oral Oncol 2015;51:514–520.
Geiger JL, Lazim AF, Walsh FJ et al.. Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma. Oral Oncol 2014;50:311–318.
Sinha P, Lewis JS Jr, Kallogjeri D et al.. Soft tissue metastasis in p16-positive oropharynx carcinoma: prevalence and association with distant metastasis. Oral Oncol 2015;51:778–786.
Lydiatt WM, Patel SG, O'Sullivan B et al.. Head and neck cancers-major changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual. CA Cancer J Clin 2017;67:122–137.
Mehra R, Ang KK, Burtness B. Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer. Semin Radiat Oncol 2012;22:194–197.
Ferris RL, Blumenschein G Jr, Fayette J et al.. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–1867.
Seiwert TY, Burtness B, Mehra R et al.. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17:956–965.
Chow LQ, Haddad R, Gupta S et al.. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort [published online ahead of print September 19, 2016]. J Clin Oncol, pii: JCO681478.
- Search Google Scholar
- Export Citation
. Chow LQ Haddad R Gupta S Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort [published online ahead of print September 19, 2016]. J Clin Oncol, pii: JCO681478.